[
    "d by calculating percent inhibition (% I) for each reaction relative to controls on the same plate (% I=(I\u2212CN)/(CP\u2212CN) where CN/CP are the averages of the negative/positive reactions, respectively), then fitting the % I data vs. compound concentration [I] to % I=(A+((B\u2212A)/(1+((C/[I]{circumflex over (0)}D)))) where A is the lower asymptote, B is the upper asymptote, C is the IC<sub>50 </sub>value, and D is the slope factor.</p>Results</p>CompoundIC<sub>50 </sub>(nM)12.122.531.941.552.464.279.686.197.0102.9113.0126.3130.6014211518162.0173.41813197.7200.81212.4222.8230.39240.77253.02620277.2280.3029113011313.6323.5336.2345.7357.7362.33715382339144051</p>FAK Biacore\u2122 SPR Assay</p>Binding parameters of compounds were determined using a Biacore\u2122 S51 sensor. An anti-GST antibody was immobilized onto a CM5 chip by primary amine-coupling in accordance with the manufacturer's recommendations.</p>In running buffer (0.01 M HEPES pH 7.4, 0.15 M NaCl, 0.005% Surfactant P20, mM MgCl<sub>2</sub>, and 1% DMSO)N-terminally GST-fused purified FAK enzyme was captured on both spot 1 and 2. Spot 1 was subsequently blocked by loading with 30 nM PF-562,271 at the beginning of each cycle. Concentration series' of the test compounds were injected over the spots at 25\u00b0 C. The specific binding was calculated as difference between spot 2 and 1 signals followed by solvent correction. Fitting to a one site binding model yielded the kinetic rate constants k<sub>d </sub>and k<sub>a </sub>and the equilibrium binding constant K<sub>D</sub>=k<sub>d</sub>/k<sub>a</sub>.</p>For compounds with an expected K<sub>D</sub>&lt;5 nM N-terminally GST-fused purified FAK enzyme was captured on spot 2 of the anti-GST antibody coated chip only. After the injection cycle of a compound the chip surface was regenerated with 10 mM glycine-HCl, pH2.2 before capturing the enzyme again. The binding sensorgrams were analysed as described before.</p>Results</p>CompoundK<sub>D </sub>(nM)10.4921.530.9140.7350.5766.372.381.097.0100.96110.61120.92130.47146.1155.0161.3173.51813197.8200.63210.44220.99231.3240.77251.126142716.6280.942912.1305.7311.0322.5335.6345.0351.6360.48</p>P397Y-FAK Inhibition MSD Platform Cellular Biomarker Assay</p>Compounds of the invention may be tested for in vitro activity in the following assay:</p>96-well plates (cat#MA6000, Meso Scale Discovery) are coated with 30 \u03bcL/well of mouse monoclonal FAK antibody [63D5](cat#ab72140, Abcam) pre-diluted in PBS to a concentration of 1 mg/mL. The plates are sealed with adhesive film and incubated for 16 hours at 4\u00b0 C. The antibody is then flicked out of the plates and 150 \u03bcL of 3% [w/v] Blocker A (cat#R93AA-1, Meso Scale Discovery) is added. The plates are resealed with adhesive film and incubated at room temperature on a shaker set at medium speed for 2 hours. The plates are then washed three times with a solution containing 50 mM Tris-HCl pH 7.5, 0.15M NaCl and 0.02% Tween-20, before cell lysate addition described below.</p>Cells are split 1",
    "4\u00b0 C. The plates are then washed three times with a solution containing 50 mM Tris-HCl pH 7.5, 0.15M NaCl and 0.02% Tween-20 and tapped dry. 25 \u03bcL/well of detection solution (1% [w/v] Blocker A (cat#R93AA-1, Meso Scale Discovery) in 50 mM Tris-HCl pH 7.5, 0.15M NaCl and 0.02% Tween-20, with 1:600 rabbit polyclonal FAK phospho Y397 antibody (cat#ab39967, Abcam), 1:1000 anti-rabbit sulfo-tag antibody (cat#R32AB-1 Meso Scale Discovery) and 1:40 reconstituted Blocker D-M (cat#D609-0100, Rockland Immunochemicals for Research)) is added, and the plates resealed with adhesive film and incubated for 1 hour at room temperature on a plate shaker set to medium speed. Plates are then washed three times with a solution containing 50 mM Tris-HCl pH 7.5, 0.15M NaCl and 0.02% Tween-20 and tapped dry. 150 \u03bcL/well of Read Buffer T+Surfactant (cat#R92TC-1, Meso Scale Discovery) is then added, and pFAK-397 levels quantified using a Meso Scale Discovery SECTOR Imager 6000 instrument.</p>IC<sub>50 </sub>values are determined by first calculating percent inhibition (% I) for each lysate relative to controls on the same plate (% I=(S\u2212CP)/(CN\u2212CP)) where S is the sample result, CN is the average result of DMSO only treated negative controls, and CP is the average result of 2 \u03bcM treated positive controls. % I is plotted against compound concentration [I] and the data fitted using the following equation, % I=(A+((B\u2212A)/(1+((C/[I])\u0302D)))), where A is the lower asymptote, B is the upper asymptote, C is the IC50 value, and D is the slope factor.</p>Results for MDA-231-LNA Cells</p>% response ofCompoundIC<sub>50 </sub>(nM)control at 2 \u03bcm15911425896327994140105570109644010872601148124105921410510371091111611212522106132611114572711636111176089188809820131112118722239123812024121072525852734110728786302811193139139332484</p>2D Cellular Proliferation Assay</p>Cells are split 1:4 into T75 cell culture flasks two days prior to cell seeding. A variety of cancer cell lines can be utilized in this assay.</p>On the day of cell seeding 100 \u03bcL/well of media containing 1000-5000 cells are added to 96-well microtitre plates (Cat.#655 180, greiner bio-one) except wells G12 and H12 to which 100 \u03bcl of media is added. In a second plate, a single row of cells is seeded at the same concentration. This second plate is known as the t=0 plate and is used to calculate the relative cell number prior to addition of test agent. The plates containing cells are incubated for 24 hours at 37\u00b0 C./5% CO<sub>2</sub>. 0.5 \u03bcL/well of compound is then added from dilution series prepared in DMSO. A compound with known potency is included for each set of plates in order to assess assay performance. Negative control wells receive the same volume of DMSO without compounds. Background signal is determined from wells containing media alone. The t=0 plate is read using addition of a resazurin-based reagent (see below) on the day that other plates have compound added to them. Plates containing cells to which compound has been added are then incubated for 3 days at 37\u00b0 C. and 5% CO<sub>2</sub>.</p>After 3 days of incubation, cell proliferation is quantified by addition of 20 \u03bcl/well of a resazurin-based reagent with a typical composition as follows: Resazurin, Sigma# R7017-1G, 0.015% w/v; methylene blue, Sigma# MB-1(25 g), 0.0025% w/v; potassium hexacyanoferrate (III), Sigma# P8131-100G, 0.033 w/v; potassium hexacyanoferrate (II) trihydrate, Sigma# P9387-100G, 0.042% w/v; in PBS buffer. Plates are incubated with resazurin-based reagent for 1-4 hours (37\u00b0 C., 5% CO<sub>2</sub>) prior to the determination of fluorescence at, or near (579<sub>Ex</sub>/584<sub>Em</sub>).</p>Percentage inhibition of proliferation (% I) for each treated well relative to controls on the same plate is calculated using the equation % I=(S\u2212B)\u2212(T<sub>0</sub>\u2212B)/(CN\u2212B)\u2212(T<sub>0</sub>\u2212B) where S is the sample result B is the background fluorescence, T<sub>0 </sub>is the t=0 value and CN is the average result of DMSO only treated negative controls. For IC50 determination, % I is plotted against compound concentration [I] and the data fitted using the following equation, % I=(A+((B\u2212A)/(1+((C/[I]){circumflex over (0)}D)))), where A is the lower asymptote, B is the upper asymptote, C is the IC<sub>50 </sub>value, and D is the slope factor.</p>Results for MDA-231-LNA Cells</p>CompoundIC<sub>50 </sub>(\u03bcM)11.1523.2131.6341.7351.5463.9171.7381.1693.58101.43112.25121.7013&gt;1.0144.49152.37162.00173.5118&gt;5191.49201.46210.80221.07234.82241.70252.8926&gt;5.5272.81281.3529&gt;530&gt;5314.1032&gt;5331.52347.8535&gt;10365.62372.7938&gt;10</p>VEGFR3Biochemical Assay</p>Compounds of the invention may be tested for in vitro activity in the following assay: A biotin labeled peptide is used as substrate (amino acid sequence: Biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>). VEGFR3 cytoplasmic domain (amino acids 798-1298) was purchased as N-terminal GST-fusion protein (\u201cthe enzyme\u201d). The 15 \u03bcl assay reactions are run in Greiner brand white 384-well low volume plates. All reactions contained 10 mM HEPES pH 7.4, mM MgCl<sub>2</sub>, 0.01% (v/v) Tween-20, 50 \u03bcM Na<sub>3</sub>VO<sub>4</sub>, 0.01% (w/v) albumin from chicken egg white, 1 mM Dithiothreitol, 111 nM peptide substrate, 500 \u03bcM ATP, and 3.8 ng/reaction enzyme, with the enzyme being omitted from negative control reactions. Compounds were added in a volume of 100 nl from dilution series prepared in DMSO, positive and negative control reactions",
    "pho VEGFR3, 100 \u03bcL of Detection antibody (Anti-Phospho-Tyrosine-HRP Detection Antibody, Part #841403 in Phospho VEGFR3 kit) was diluted in IC Diluent #1 (1% w/v BSA/PBS), added to the wells and the plate incubated for 2 hours at room temperature. The plate was then washed three times in wash buffer as described above and tapped dry. 100 \u03bcL Substrate solution (3,3\u2032,5,5\u2032-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA, Cat # T0440, Sigma-Aldrich) was added and the plate incubated for 20 minutes in the dark at room temperature followed by the addition of 50 \u03bcL stop solution (2N H<sub>2</sub>SO<sub>4</sub>).</p>Phospho VEGFR3 levels were quantified using a Multiscan ascent plate reader and ascent software fitted with 450 nm filter.</p>IC<sub>50 </sub>values are determined by first calculating the level of phospho VEGFR3 relative to Total VEGFR3 according to the following formula:</p>S\ue89e\ue89eR\ue89e\ue89eP=SPST</p>where SRP is the Sample Relative Phospho level, SP is Phospho VEGFR3 reading and ST is Total VEGFR3 reading.</p>Percent inhibition (% I) for each lysate relative to vehicle control (VEGF-C stimulated) is then calculated according to the following formula:</p>%\ue89e\ue89eI=S\ue89e\ue89eR\ue89e\ue89eP\ue89e\ue89eVehicle-S\ue89e\ue89eR\ue89e\ue89eP\ue89e\ue89eTestS\ue89e\ue89eR\ue89e\ue89eP\ue89e\ue89eVehicle*100</p>where SRP is the Sample Relative Phospho level as calculated above.</p>% I is plotted against compound concentration and data fitted using a Sigmoidal dose response curve (GraphPad Prism 4 for Windows) with the following equation (Y=Bottom+(Top-Bottom)/(1+10\u0302 (LogEC50-X))) where X is the logarithm of the concentration, Y is the response. Y starts at Bottom and goes to Top with a sigmoid shape.</p>CompoundIC<sub>50 </sub>(nM)380524081271167128116361744203021113223024712566306583167338136169</p>Results</p>Combination Study\u2014Survival Advantage in the MDA-231-LNA Orthotopic Xenograft Model</p>2\u00d710<sup>6 </sup>MDA-231-LNA cells in sterile PBS were injected into the mammary fat pad of female Balb/c SCID mice (6-8 weeks, n=10 per group). Once the tumours were palpable (day 14 post injection of cells) mice were treated once daily with vehicle; hydroxypropylmethylcellulose vehicle (HPMC-SV; 0.2 ml/dose), Avastin (12.5 mg/kg i.p. twice weekly), compound 16 p.o. 54 mg/kg BID or a combination of Avastin and compound 16 at the doses described above.</p>Compound 16 was formulated as the citrate salt in hydroxypropylmethylcellulose suspension vehicle (HPMC-SV) and delivered orally in 0.2 ml. Avastin (clinical formulation; Roche, Dee Why, New South Wales, Australia) was diluted in phosphate buffered saline and administered by intraperitoneal injection in 0.2 ml.</p>With the exception of three mice per group that were culled after 13 days of dosing for immunohistochemical analysis of tumour vascular density and mature macrophage infiltration, all other mice were killed by isoflurane anaesthesia and cervical dislocation when tumours reached 1500 mm<sup>3</sup>. Mice harvested for tumour immunohistochemical analysis were not included in Kaplan-Meier a"
]